INDIVIOR PLC (INDV) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

Low Risk
Limited dilution potential
Last updated: May 04, 2026

Risk Assessment Details

Potential Dilution: 0.0% of current shares
Recent Dilution: 0% (2 years)
Historical Dilution Factor: minimal recent dilution
Outstanding Shares
120M
Potential Supply
0
Additional shares possible
Splits
None
Past 2 years

Summary

INDV currently has 124M outstanding shares. with minimal authorized share overhang for future dilution. The company has not diluted shareholders through share issuances in the past 2 years, which is positive for existing holders.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
May 04, 2026

8-K filing: Indivior Pharmaceuticals, Inc. entered into an accelerated share repurchase agreement (ASR Agreement) with a Counterparty Bank to repurchase $175.0 million of shares of the Company's common stock as part of the Company's previously announced $400 million share repurchase program. ($175.0M proceeds)

120M 0
Apr 30, 2026

10-Q filing | 124.0M shares outstanding

120M 0
Mar 17, 2026

8-K filing: Indivior Pharmaceuticals, Inc. issued $500,000,000 principal amount of 0.625% Convertible Senior Notes due 2031, with an option for initial purchasers to buy an additional $50,000,000.

130M 0
Oct 30, 2025

10-Q filing | 125.0M shares outstanding

130M 0
Jun 24, 2025

8-K filing: Non-executive directors entered into a Purchase Plan with J.P Morgan Securities LLC, allowing them to defer a portion of their retainer fee into Company shares, and Juliet Thompson purchased 1,925 Ordinary Shares and Timothy Thompson purchased 3,850 Ordinary Shares, which will be reimbursed by the company.

130M 0
May 01, 2025

10-Q filing | 125.0M shares outstanding

130M 0
Mar 04, 2025

8-K filing: Indivior PLC entered into an employment agreement with Joe Ciaffoni, including performance stock units and restricted stock units grants, and amended its Relationship Agreement with Oaktree Capital Partners, appointing Joe Ciaffoni and Daniel Ninivaggi to the board.

130M 0
Mar 03, 2025

10-K filing | 132.0M shares outstanding

130M 0
Mar 06, 2024

20-F filing | 136.5M shares outstanding

140M 0
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime